While Tirzepatide is a dual agonist (GIP/GLP-1), the triple nature of Retatrutide adds the glucagon component
Although there have been no specific trials to show cardiorenal benefit for GLP-1RA or SGLT2i when used as first-line therapy or as monotherapy or in newly diagnosed T2D, the benefit seen in the CV outcome trials has not been found to vary with the duration of diabetes, suggesting that similar benefits might be seen early in the course of disease.4 The benefits are also not dependent on the presence of metformin
The people who took retatrutide also reported a 76% reduction in knee pain after the 16 months, according to the data
It provides ongoing support so your body can maintain a lower, healthier weight
Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa Key Players Insights Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca Perrigo Company PLC 3M Company Bausch Health Taro Pharmaceutical Industries Novan Inc
Tying medication access to mandatory lifestyle hoops creates another barrier to care
